Live market news
Stocks
ACXP

Acurx Pharmaceuticals Inc.

ACXPStockUnited States

See in Charts

Latest news on ACXPranked by Oyticker for market impact

45Impact
Positive29 Sept 2026 · 14:40 UTC · Global · Medium term
ACXP enrolls first patient in PATHFINDER Phase 3 trial for ibezapolstat in recurrent C. difficile
Acurx Pharmaceuticals announced first-patient enrollment in its PATHFINDER Phase 3 clinical trial evaluating ibezapolstat for multiply-recurrent C. difficile infection, a late-stage development milestone for its novel antibiotic candidate.
ACXPBiopharmaceuticalsSpecialty Pharmaceuticals

SEC filings

What ACXP filed

All its filings

29 Oct 2026
Bylaws or fiscal year changed (opens the document on sec.gov)8-K
16 Oct 2026
Shareholder vote results (opens the document on sec.gov)8-K
8 Sept 2026
Registration for a listing (opens the document on sec.gov)S-1
1 Sept 2026
Proxy statement (opens the document on sec.gov)DEF 14A
13 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
11 May 2026
Quarterly report (opens the document on sec.gov)10-Q

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on ACXPranked by Oyticker for market impact

ACXP enrolls first patient in PATHFINDER Phase 3 trial for ibezapolstat in recurrent C. difficile

What ACXP filed